{"id":3892,"date":"2019-01-03T15:33:16","date_gmt":"2019-01-03T10:03:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3892"},"modified":"2021-07-24T12:57:10","modified_gmt":"2021-07-24T07:27:10","slug":"the-business-cocktail-50","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50","title":{"rendered":"Atlas Venture raises; Harpoon files IPO; Boston Scientific bags Millipede"},"content":{"rendered":"\n<p><strong>Atlas\nVenture raises USD 250 Million for investing in later-stage<\/strong><\/p>\n\n\n\n<p class=\"has-background has-cyan-bluish-gray-background-color\"><strong>Massachusetts-based Atlas Venture <\/strong>has&nbsp;raised <strong>USD 250 million<\/strong> for later-stage investments. The fund will allow the VC shop to bolster its startups through<strong> series B<\/strong> and beyond. The early-stage operation has bolstered a couple of startups like <strong>Padlock and Unum Therapeutics<\/strong>, to IPOs and trade sales. <strong>Atlas Venture Opportunity Fund I (AVOF I)<\/strong> is the VC shop\u2019s remedy for financial requirements. Atlas Venture has <strong>USD 250 million<\/strong> to support the portfolio companies as they reach series B and beyond.<\/p>\n\n\n\n<p><strong>Harpoon\nfiles USD 86 Million IPO for funding its T-cell engager platform<\/strong><\/p>\n\n\n\n<p class=\"has-background has-cyan-bluish-gray-background-color\"><strong>Harpoon Therapeutics<\/strong> declared for going public with a<strong> USD 86.25 million<\/strong> <strong>IPO <\/strong>to bolster its portfolio of <strong>early-stage <a href=\"https:\/\/www.delveinsight.com\/report-store\/t-cell-inhibitor-pipeline-insight\">T-cell <\/a>engagers<\/strong> aimed at solid <g class=\"gr_ gr_26 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling multiReplace\" id=\"26\" data-gr-id=\"26\">tumors<\/g>. The South San Francisco-based company filed privately with the SEC which had brought on new investors including <strong>OrbiMed, Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures and NS Investment<\/strong>.<\/p>\n\n\n\n<p><strong>Boston\nScientific bags Millipede and its device for USD 325 Million<\/strong><\/p>\n\n\n\n<p class=\"has-background has-cyan-bluish-gray-background-color\"><strong>Millipede and Boston Scientific<\/strong> inked the agreement, <strong>Boston Scientific<\/strong> gave <strong>USD 90 million<\/strong> for a portion of the <strong>mitral regurgitation<\/strong> startup\u2019s shares and now the device maker is&nbsp;remunerating <strong>USD 325 million<\/strong> to pick up the rest shares of <strong>Millipede<\/strong>. Boston Scientific could choose to give USD 325 million and commit to remunerate a USD 125 million commercial <g class=\"gr_ gr_6 gr-alert gr_gramm gr_inline_cards gr_disable_anim_appear Grammar multiReplace\" id=\"6\" data-gr-id=\"6\">milestone<\/g> to acquire Millipede at any time before it finishes a clinical trial. Alternatively, after completing that trial, Millipede could have forced Boston Scientific to acquire it.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Atlas Venture raises USD 250 Million for investing in later-stage Massachusetts-based Atlas Venture has&nbsp;raised USD 250 million for later-stage investments. The fund will allow the VC shop to bolster its startups through series B and beyond. The early-stage operation has bolstered a couple of startups like Padlock and Unum Therapeutics, to IPOs and trade sales. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3895,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1036,2364,1728,2365],"industry":[17225],"therapeutic_areas":[],"class_list":["post-3892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-atlas-venture","tag-atlas-venture-opportunity-fund-i-avof-i","tag-ipo","tag-millipede","industry-pharmaceutical"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Atlas raises $250m; Harpoon&#039;s $86M IPO; Boston-Millipede&#039;s agreement<\/title>\n<meta name=\"description\" content=\"Massachusetts-based Atlas Venture has raised USD 250 million for later-stage investments. The fund will allow the.........\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atlas raises $250m; Harpoon&#039;s $86M IPO; Boston-Millipede&#039;s agreement\" \/>\n<meta property=\"og:description\" content=\"Massachusetts-based Atlas Venture has raised USD 250 million for later-stage investments. The fund will allow the.........\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-03T10:03:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Atlas raises $250m; Harpoon's $86M IPO; Boston-Millipede's agreement","description":"Massachusetts-based Atlas Venture has raised USD 250 million for later-stage investments. The fund will allow the.........","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50","og_locale":"en_US","og_type":"article","og_title":"Atlas raises $250m; Harpoon's $86M IPO; Boston-Millipede's agreement","og_description":"Massachusetts-based Atlas Venture has raised USD 250 million for later-stage investments. The fund will allow the.........","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-01-03T10:03:16+00:00","article_modified_time":"2021-07-24T07:27:10+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50","name":"Atlas raises $250m; Harpoon's $86M IPO; Boston-Millipede's agreement","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg","datePublished":"2019-01-03T10:03:16+00:00","dateModified":"2021-07-24T07:27:10+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Massachusetts-based Atlas Venture has raised USD 250 million for later-stage investments. The fund will allow the.........","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-50#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co.jpg","width":1920,"height":1080,"caption":"Juvenescence"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103834\/bus-co-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atlas Venture<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atlas Venture Opportunity Fund I (AVOF I)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IPO<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Millipede<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Atlas Venture<\/span>","<span class=\"advgb-post-tax-term\">Atlas Venture Opportunity Fund I (AVOF I)<\/span>","<span class=\"advgb-post-tax-term\">IPO<\/span>","<span class=\"advgb-post-tax-term\">Millipede<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 3, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 3, 2019 3:33 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3892"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3892\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3895"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3892"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3892"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}